Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Neurology\Neurosurgery
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Neurology\Neurosurgery. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Case 32-2017: A 64-Year-Old Man with Dyspnea, Wheezing, Headache, Cough, and Night Sweats
01/01/70 - Presentation of Case. Dr. Amulya Nagarur: A 64-year-old man was evaluated in the emergency department of this hospital because of dyspnea, wheezing, headaches, cough, and night sweats. Approximately 6 years before this presentation, the patient had received a diagnosis of fibromyalgia, which had…

Incidental Findings on Brain Imaging in the General Pediatric Population
01/01/70 - To the Editor: Incidentally discovered findings on brain magnetic resonance imaging (MRI) in healthy persons pose medical and ethical considerations regarding management. The prevalence of incidental findings on brain MRI has been described in adult populations, but less is known about incidental…

An Element of Unsteadiness
01/01/70 - Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information, sharing his or her reasoning with the reader (regular type). The authors? commentary follows. Stage. A 61-year-old woman presented with…

Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
01/01/70 - Adrenoleukodystrophy is an X-linked genetic disease that is caused by a defect in the gene ABCD1 (ATP-binding cassette, subfamily D, member 1), which encodes the peroxisomal ABC half-transporter ALD protein. Mutations in ABCD1 result in abnormal breakdown of very-long-chain fatty acids, a process…

Optimizing Treatment for Cerebral Adrenoleukodystrophy in the Era of Gene Therapy
01/01/70 - Adrenoleukodystrophy is a peroxisomal metabolic disorder that can be manifested by rapidly progressive cerebral demyelination (known as cerebral adrenoleukodystrophy) in affected boys and men. Untreated cerebral adrenoleukodystrophy causes severe disability or death approximately 2 years after its…

Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
01/01/70 - Case?control studies have shown an association between patent foramen ovale (PFO) and cryptogenic stroke, particularly among patients younger than 55 years of age and among patients with an associated atrial septal aneurysm or a substantial right-to-left interatrial shunt. The role of closure of…

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
01/01/70 - Between 20 and 30% of ischemic strokes are cryptogenic. A strong association between cryptogenic strokes and the presence of patent foramen ovale (PFO) suggests that paradoxical embolism through a PFO may be one important cause of otherwise unexplained infarcts. Percutaneous devices for closure of…

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
01/01/70 - Patent foramen ovale (PFO) is a potential cause of cryptogenic stroke. Three previous randomized trials of transcatheter PFO closure did not show a lower risk of recurrent stroke with PFO closure than with medical therapy in their primary intention-to-treat analyses; however, secondary analyses…

Tipping Point for Patent Foramen Ovale Closure
01/01/70 - On the basis of what I had read previously in the Journal, I recently explained to my 44-year-old patient that closing his patent foramen ovale (PFO) after his stroke was not advisable. How can we now have three trials showing that closure prevents recurrent stroke, given that in the past 5 years,…

Patent Foramen Ovale after Cryptogenic Stroke ? Assessing the Evidence for Closure
01/01/70 - The Amplatzer PFO Occluder was approved by the Food and Drug Administration (FDA) on October 28, 2016. The device is indicated for percutaneous transcatheter closure of a patent foramen ovale to reduce the risk of recurrent ischemic stroke in patients who?ve had a cryptogenic stroke that a…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins